Answers are grounded in this paper and cite their sources.
Assesses the transportability of tislelizumab efficacy in European lung cancer patients, indicating similar outcomes to Asian trials.
BACKGROUND: Tislelizumab was evaluated in randomized controlled trials (RCTs) for non-small cell lung cancer (NSCLC) (RATIONALE-315, RATIONALE-303) and extensive-stage small cell lung cancer (ES-SCLC) (RATIONALE-312), primarily in Asian populations. We assessed the transportability of clinical findings from these RCTs to European patients. METHODS: Targeted literature reviews (TLRs) identified real world-evidence (RWE), RCTs, and treatment effect modifiers in perioperative NSCLC, second-line or later (2L+) NSCLC, and first-line (1L) ES-SCLC. Relevant RWE studies were selected to define the target European-like populations. Outcome regression models used RATIONALE individual patient data to predict relative treatment effect of tislelizumab vs. comparators in European populations. RESULTS: Event-free survival (HR 0.56), major pathological response (OR 7.49) and pathological complete response (OR 11.54) from RATIONALE-315 were similar to those predicted for the base case European target perioperative NSCLC population (EFS HR 0.57; MPR OR 3.39; PCR OR 8.95). Predicted overall survival and progression-free survival for 2L+ NSCLC and for 1L ES-SCLC were similar to RATIONALE-303 and RATIONALE-312, respectively. CONCLUSION: The efficacy of tislelizumab observed in the RATIONALE trials explored in this analysis is transportable, subject to the specified assumptions, to European patients in the setting of perioperative NSCLC, 2L+ NSCLC, and 1L ES-SCLC, consistently favoring tislelizumab over control.
No takes yet. Share an insight, caveat, or question.
Passiglia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: